AU2017248762A1 - Combinations for the treatment of neoplasms using quiescent cell targeting and EGFR inhibitors - Google Patents

Combinations for the treatment of neoplasms using quiescent cell targeting and EGFR inhibitors Download PDF

Info

Publication number
AU2017248762A1
AU2017248762A1 AU2017248762A AU2017248762A AU2017248762A1 AU 2017248762 A1 AU2017248762 A1 AU 2017248762A1 AU 2017248762 A AU2017248762 A AU 2017248762A AU 2017248762 A AU2017248762 A AU 2017248762A AU 2017248762 A1 AU2017248762 A1 AU 2017248762A1
Authority
AU
Australia
Prior art keywords
cancer
pct
egfr tki
neoplasm
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017248762A
Other languages
English (en)
Inventor
Marc DUEY
Michael Frid
Yuriy GANKIN
Alexandra KUZNETSOVA
Maria Vilenchik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Felicitex Therapeutics Inc
Original Assignee
Felicitex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Felicitex Therapeutics Inc filed Critical Felicitex Therapeutics Inc
Publication of AU2017248762A1 publication Critical patent/AU2017248762A1/en
Priority to AU2023200428A priority Critical patent/AU2023200428A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017248762A 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and EGFR inhibitors Abandoned AU2017248762A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023200428A AU2023200428A1 (en) 2016-04-15 2023-01-27 Combinations for the treatment of neoplasms using quiescent cell targeting and EGFR inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323537P 2016-04-15 2016-04-15
US62/323,537 2016-04-15
PCT/US2017/027719 WO2017181075A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200428A Division AU2023200428A1 (en) 2016-04-15 2023-01-27 Combinations for the treatment of neoplasms using quiescent cell targeting and EGFR inhibitors

Publications (1)

Publication Number Publication Date
AU2017248762A1 true AU2017248762A1 (en) 2018-11-01

Family

ID=60039950

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017248762A Abandoned AU2017248762A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and EGFR inhibitors
AU2023200428A Abandoned AU2023200428A1 (en) 2016-04-15 2023-01-27 Combinations for the treatment of neoplasms using quiescent cell targeting and EGFR inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023200428A Abandoned AU2023200428A1 (en) 2016-04-15 2023-01-27 Combinations for the treatment of neoplasms using quiescent cell targeting and EGFR inhibitors

Country Status (11)

Country Link
US (3) US10322128B2 (https=)
EP (1) EP3442505A4 (https=)
JP (2) JP7123806B2 (https=)
KR (2) KR102494174B1 (https=)
CN (1) CN109562176A (https=)
AU (2) AU2017248762A1 (https=)
BR (1) BR112018071031A2 (https=)
CA (1) CA3021021A1 (https=)
IL (2) IL262323B (https=)
MX (2) MX2018012511A (https=)
WO (1) WO2017181075A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3400003B1 (en) * 2016-01-05 2023-05-03 The Trustees of Columbia University in the City of New York Compositions for regulating activity of inhibitor of dna binding-2 (id2) protein
EP3443351A4 (en) 2016-04-15 2019-12-18 Felicitex Therapeutics, Inc. COMBINATIONS FOR THE TREATMENT OF NEOPLASIA BY TARGETING RESTING CELLS AND INHIBITORS OF MITOSIS
CA3021021A1 (en) * 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES
WO2020235973A1 (ko) * 2019-05-22 2020-11-26 주식회사 보로노이 암의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
CN117479943A (zh) * 2021-06-15 2024-01-30 基因泰克公司 组合疗法中的egfr抑制剂和perk活化剂及其用于治疗癌症的用途
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
CN115947673B (zh) * 2022-12-19 2024-03-15 湖南岳靶生物医药有限公司 一种化疗药物增敏剂、组合物及其应用
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560004A1 (de) * 2011-08-19 2013-02-20 DST Diagnostische Systeme & Technologien GmbH Neues PoC-Testsystem und Verfahren
US9446044B2 (en) 2011-08-19 2016-09-20 Diaxonhit DYRK1 inhibitors and uses thereof
JP2015534584A (ja) 2012-10-10 2015-12-03 フェリシテックス・セラピューティクス，インコーポレイテッド 静止癌細胞の標的化による癌の治療
CA2854542A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
CN106535890A (zh) 2014-03-20 2017-03-22 萨穆梅德有限公司 5‑取代的吲唑‑3‑羧酰胺及其制备和应用
EP3191523B1 (en) 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US20170304313A1 (en) * 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
ES2917526T3 (es) * 2015-07-23 2022-07-08 Calgent Biotechnology Co Ltd Compuestos de aminonaptoquinona y composición farmacéutica para bloquear el sistema ubiquitinación-proteasoma en enfermedades
EP3443351A4 (en) 2016-04-15 2019-12-18 Felicitex Therapeutics, Inc. COMBINATIONS FOR THE TREATMENT OF NEOPLASIA BY TARGETING RESTING CELLS AND INHIBITORS OF MITOSIS
CA3021021A1 (en) 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors

Also Published As

Publication number Publication date
MX2018012511A (es) 2019-07-08
CN109562176A (zh) 2019-04-02
IL262323B (en) 2022-03-01
EP3442505A4 (en) 2019-12-18
US20190298723A1 (en) 2019-10-03
KR20230020565A (ko) 2023-02-10
AU2023200428A1 (en) 2023-03-02
WO2017181075A1 (en) 2017-10-19
US20220110940A1 (en) 2022-04-14
EP3442505A1 (en) 2019-02-20
JP7123806B2 (ja) 2022-08-23
MX2023000549A (es) 2023-02-13
KR102494174B1 (ko) 2023-02-02
KR20180132882A (ko) 2018-12-12
JP2022145800A (ja) 2022-10-04
US10322128B2 (en) 2019-06-18
US20170296541A1 (en) 2017-10-19
CA3021021A1 (en) 2017-10-19
BR112018071031A2 (pt) 2019-02-12
JP2019511554A (ja) 2019-04-25
US11202779B2 (en) 2021-12-21
IL288777A (en) 2022-02-01
IL262323A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
US11202779B2 (en) Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
US20220110941A1 (en) Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
WO2023140846A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
JP6637884B2 (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
JP2018535996A (ja) 血液癌を処置するためのセルデュラチニブ
KR102382771B1 (ko) 증식성 질환을 위한 조합 치료
Liu et al. An overview of pim kinase as a target in multiple myeloma
US20100226919A1 (en) Antitumoral Treatments
JP2022507260A (ja) Ｍｃｌ－１阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物
US20230226061A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
HK40059071A (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted